Pancreatic Elastase Testing Market Size & Share, by Application (Cystic Fibrosis, Diabetes Mellitus, Chronic Pancreatitis, Pancreatic Insufficiency); End-user (Diagnostic Centers, Hospitals, Clinics, Pathology Laboratories, Research Centers) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2024-2036

  • Report ID: 4043
  • Published Date: Sep 16, 2024
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2024-2036

Pancreatic Elastase Testing Market size was valued at USD 16.28 billion in 2023 and is likely to reach USD 43.22 billion by the end of 2036, expanding at around 7.8% CAGR during the forecast period i.e., between 2024-2036. In the year 2024, the industry size of pancreatic elastase testing is assessed at USD 17.3 billion.

Pancreatic elastase test, also known as, fecal elastase, is used to test the amount of elastase produced in the body. Elastase is an enzyme secreted by the pancreas to break down fats, proteins, and carbohydrates. The growth of the market can be attributed to the increasing prevalence of pancreatic insufficiency, chronic pancreatitis, and others. According to a report published by National Center for Biotechnology Information and StatPearls Publishing, chronic pancreatitis occurs in 42 to 73 individuals per 100,000 of the population in the United States, while the prevalence in Japan, China, and India is around 36 to 125 per 100,000 individuals, as of 2021. Moreover, improvement in the diagnostic technologies, penetration of AI in medical diagnostics, and rising awareness amongst people regarding tests and diagnosis are anticipated to boost the market growth. Furthermore, the increasing healthcare expenditure across the globe, is forecasted to encourage the growth of the market.


Pancreatic-Elastase-Testing-Market
Get more information on this report: Request Free Sample PDF

Pancreatic Elastase Testing Sector: Growth Drivers and Challenges

Growth Drivers

  • Increasing Prevalence of Chronic Pancreatitis
  • Rapid Advancement in the Diagnostic Technologies
  • High Global Health Expenditure

Challenges

  • Requirement of High Initial Investment
  • Lack of Researchers and Practitioners in Pathological Science 

Pancreatic Elastase Testing Market: Key Insights

Base Year

2023

Forecast Year

2024-2036

CAGR

7.8%

Base Year Market Size (2023)

USD 16.28 billion

Forecast Year Market Size (2036)

USD 43.22 billion

Regional Scope

  • North America (U.S., and Canada)
  • Asia Pacific (Japan, China, India, Indonesia, South Korea, Malaysia, Australia, Rest of Asia Pacific)
  • Europe (UK, Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Latin America (Mexico, Argentina, Brazil, Rest of Latin America)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Get more information on this report: Request Free Sample PDF

Pancreatic Elastase Testing Segmentation

The market is segmented by application into cystic fibrosis, diabetes mellitus, chronic pancreatitis, pancreatic insufficiency, and others out of which, the chronic pancreatitis segment is anticipated to hold a substantial share in the global pancreatic elastase testing market over the forecast period. The growth of the segment can be accredited to the high prevalence of chronic pancreatitis across the globe, along with the rising cases of pancreatic cancer. Pancreatitis, if left untreated, can lead to cancer in the pancreas. The growth in the average alcohol consumption, as a part of the changing modern lifestyle, is also estimated to encourage the segment growth, as alcohol consumption is a major cause for chronic pancreatitis. 

Our in-depth analysis of the global pancreatic elastase testing market includes the following segments

By Application

  • Cystic Fibrosis
  • Diabetes Mellitus
  • Chronic Pancreatitis
  • Pancreatic Insufficiency
  • Others

By End-User

  • Diagnostic Centers
  • Hospitals and Clinics
  • Pathology Laboratories
  • Research Centers
  • Others

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Pancreatic Elastase Testing Industry - Regional Synopsis

APAC Market Statistics

On the basis of geographical analysis, the global pancreatic elastase testing market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. Asia Pacific industry is predicted to account for largest revenue share by 2036, impelled by improving healthcare infrastructure in the developing countries, along with growing prevalence of pancreatic cancer in the region.

North America Market Analysis

The pancreatic elastase testing market in the North America region is anticipated to gain a significant market share throughout the forecast period owing to the growing prevalence of chronic pancreatitis in the region. According to the data by the National Pancreas Foundation, the prevalence of chronic pancreatitis is 50 per 100,000 individuals in the United States, and is more common in men than women.

On the other hand, the pancreatic elastase testing market in Europe occupied the largest market share in 2021, owing to the presence of the advanced healthcare facilities, favorable health insurance and reimbursement policies, and high healthcare expenditure in the developed countries, such as, Germany, Switzerland, France, Sweden, Norway, and Denmark.  

Research Nester
Pancreatic-Elastase-Testing-Market-Share
Get more information on this report: Request Free Sample PDF

Companies Dominating the Pancreatic Elastase Testing Landscape

    • Thermo Fisher Scientific Inc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis 
    • Bio-Rad Laboratories, Inc.
    • F. Hoffmann-La Roche Ltd.
    • Hologic, Inc.
    • BIOMERIEUX PLC
    • Becton, Dickinson and Company
    • Bioserv Diagnostics Gmbh
    • Novozymes A/S
    • AB Enzymes GmbH
    • Buhlmann Diagnostics Corp

In the News

  • March 16, 2022: Thermo Fisher Scientific introduced a new large-volume electroporation system for cell therapy developers to facilitate commercial manufacturing of clinical therapy systems.

  • December 12, 2021: AB Enzymes to form a joint membership with Europa Bio, to promote the benefits of the biotech industry, and work towards a sustainable environment.

Author Credits:  Radhika Pawar


  • Report ID: 4043
  • Published Date: Sep 16, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

The increasing prevalence of chronic pancreatitis is estimated to boost the market growth.

The market is anticipated to attain a CAGR of ~6% over the forecast period, i.e., 2022 – 2031.

The lack of researchers and practitioners in pathological science is estimated to hamper the market growth.

The North America region is anticipated to provide more business opportunities over the forecast period owing to the growing prevalence of chronic pancreatitis in the region.

The major players in the market are Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd., Hologic, Inc., BIOMERIEUX PLC, Bioserv Diagnostics Gmbh, Novozymes A/S, AB Enzymes GmbH, and Buhlmann Diagnostics Corp.
Pancreatic Elastase Testing Market Report Scope
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample